At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Ara-C +2 moredrug
Likely dose
Ara-C 3000mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating Ara-C, Mitoxantrone, and 1 other intervention for Myelodysplastic Syndrome and Acute Myeloid Leukemia. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome, Acute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2002
First PostedOct 2008
Primary CompletionMar 2011
TodayJul 2026
First PostedOct 16, 2008
Enrollment StartDec 1, 2002
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 17.7 years ago
Interventions
Ara-Cdrug
Induction: 3000mg/m2 IV infusion for day 1 and day 5 Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)
Mitoxantronedrug
Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
Etoposidedrug
Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days